61 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
7 May 24
Cogent Biosciences Reports First Quarter 2024 Financial Results
8:19am
at the American Society of Clinical Oncology (ASCO) annual meeting taking place May 31-June 4, 2024. PEAK is the Company’s ongoing Phase 3 trial evaluating
8-K
EX-99.1
ysmgo2eqngc
26 Feb 24
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
8:30am
8-K
gnuoae
11 Dec 23
Other Events
8:04am
8-K
EX-99.1
ng1ss
2 Nov 23
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
9:18am
424B5
fmjg wv4nql40p
8 Jun 23
Prospectus supplement for primary offering
4:01pm
424B5
jd3sl9rorm18zobnj
6 Jun 23
Prospectus supplement for primary offering
5:22pm
8-K
f4y1l0a6zim8p2ni
6 Jun 23
Other Events
4:03pm
8-K
EX-99.1
xdwcr7iz 17
9 May 23
Cogent Biosciences Reports Recent Business Highlights and First Quarter
8:13am
8-K
EX-99.2
ic0r9x
12 Dec 22
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
8:03am
8-K
EX-99.1
w57a fe9nw5ccd4f
12 Dec 22
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
8:03am
8-K
EX-99.1
yti4cf j88ixk0f
14 Nov 22
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
7:14am